Floatz logo

Ibrutinib

Autoimmune Hemolytic Anemia

Gruppo Italiano Malattie EMatologiche dell'AdultoSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Autoimmune Hemolytic Anemia cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Phase 2B
Cyclophosphamide
City of Hope Medical Center
Phase 2B
PREDNISONE TABLETS
City of Hope Medical Center
Phase 2CCC
Acalabrutinib
City of Hope Medical Center
Phase 2CCC
Thiotepa
University of Florida
Phase 1/2CCC

View all 13 →

Same molecule, other indications

Ibrutinib is also rated in:

lymphoid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
70 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →